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Abstract  
Aseptic loosening, as a consequence of an extended inflammatory reaction induced by 
wear particles, has been classified as one of the most common complications of total 
joint replacement (TJR). Despite its high incidence, no therapeutical approach has yet 
been found to prevent aseptic loosening, leaving revision as only effective treatment. 
The local delivery of anti-inflammatory drugs to modulate wear-induced inflammation has 
been regarded as a potential therapeutical approach to prevent aseptic-loosening. In this 
context, we developed and characterised an anti-inflammatory drug-eluting TiO2 sur-
faces, using naniparticles as a model for larger surfaces. The eluting surfaces were ob-
tained by conjugating dexamethasone to carboxyl-functionalised TiO2 particles, obtained 
by using either silane agents with amino or mercapto moieties. 
Zeta potential measurements, thermogravimetric analysis (TGA) and drug release re-
sults suggest that dexamethasone was successfully loaded onto the TiO2 particles. Re-
lease was pH dependent and greater amounts of drug were observed from amino route 
functionalized surfaces. The model-system was then tested for its cytotoxic and anti-
inflammatory properties in LPS-stimulated macrophages. Dexamethasone released from 
amino route functionalized surfaces TiO2 particles was able to decrease LPS-induced 
nitric oxide (NO) and TNF-a production similarly to pure DEX at the same concentration; 
DEX released from mercapto route functionalized surfaces was at a too low concentra-
tion to be effective.  
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1 Introduction 
Joint degenerative and inflammatory diseases e.g. arthritis affect the quality of life of 
millions people worldwide.1 One of the ways to help people affected by such disease is 
to have artificial implants such as total joint replacement (TJR).2-4 Even though the suc-
cess of these procedures has been widely recognized, so far it is not yet possible to 
overcome wear-debris induced osteolysis, a process that leads to aseptic loosening. TJR 
associated osteolysis is difficult to treat and, in most of cases, requires the complete 
removal of the implant. This procedure is costly and time-consuming for both patients 
and health services due to its complexity, high risk and often suboptimal surgical out-
come.5 According to National UK Joint Registry 9% of hip and 6% of knee primary pro-
cedures undertaken in UK during 2015, resulted in revision surgery. Of those recorded, 
aseptic loosening was the cause for total hip and knee revision procedures in 42% and 
41% of cases, respectivelly.6 
Althought different theories have been proposed to explain TJR aseptic loosening,7 it is 
generally accepted that the factors leading to osteolysis involve the release of wear par-
ticles originated during the articulation of the joint device.8,9 Wear debris triggers an in-
flammatory reaction, which leads to osteoclast differention and osteoblast down-regula-
tion, thus ultimately resulting in local bone (osteolysis) loss around the implant.   
In order to overcome such adverse event, research has concentrated on methods to 
enhance osseointegration and diminish the release of wear particles in orthopaedic im-
plants.2,9,10 For this purpose, alternative bearing materials, such as cross-linked polyeth-
ylene, zirconium/zirconia combination, titanium and cobalt based alloys, and polycar-
bonate-urethane have been suggested.11,12 Also the application of surface treatments 
such as plasma spraying, grit-blasting, acid-etching, and electrochemical-anodization 
have been applied to mitigate the risk of osteolytic reaction.2,13,14 However, some of these 
  
 
 
methods have been reported to affect the physical integrity of the implant, hence causing 
adverse effects on surrounding cells and tissues.15,16 
A more recent approach to address wear debris-induced aseptic loosening is the direct 
modulation of the inflammatory response by using implant surfaces eluting anti-inflam-
matory drugs.17,18 The main advantage of these systems is the local delivery of anti-
inflammatory molecules which simultaneously modulate inflammation and avoid possible 
side effects caused by a long-term and high-concentration systemic drug administration, 
most notably the gastrointestinal and cardiovascular adverse effects.19 Implantable bio-
materials and devices with different anti-inflammatory delivery systems have been re-
ported in literature, such as bone cements,20 nanotubes,21,22 dendrimer-conjugates,23,24 
N-(2-hydroxypropyl) methacrylamide (HPMA) co-polymer17,25 and polylactic-co-glycolic 
acid (PLGA) microspheres.26 Beside anti-inflammatory activity,27 these systems have 
also shown several advantages in orthopedic applications such as improved biological 
activity in terms of osteoblasts attachment, proliferation and differentiation.28,29 Although, 
the utilization of anti-inflammatory drug-eluting implants have shown some significant 
improvements, most of them are still in early research stage. 
Particularly, in most of the drug delivery systems described in literature, the anti-inflam-
matory drug is released in uncontrolled manner i.e. burst release and within the first week 
after implantation. This short-timed and uncontrolled released is not long enough to mod-
ulate the acute phase of inflammation, which can last for more than one week. Long 
acute inflammation can possibly result in chronic inflammation, which is characterized 
by poor tissue healing which creates mechanical instability around the implant. This 
leads to the conclusion that no effective solutions to avoid or treat aseptic loosening have 
been yet found. Therefore, it is evident that the development of novel and better ap-
proaches to modulate wear-debris induced inflammatory response are needed. 
  
 
 
The present study aims to develop an anti-inflammatory drug-eluting model system on 
titanium surface, to modulate the wear-debris induced inflammation, which has been elu-
cidated as the central mechanism for aseptic loosening. Due to its cost-effective charac-
teristics, high surface area and easy scale-up,30,31 TiO2 particles have been utilized as a 
drug delivery model system. It is also worth noting that the surface modifications per-
formed on TiO2 particles could be conducted on the surface of clinically used implants 
made of titanium and titanium alloys, which are regarded as the one of most widely used 
biomaterials in joint replacements.32 Therefore, the model system may serve as proof of 
concept to incorporate anti-inflammatory drugs in implant materials for total joint replace-
ments made of titatium and titanium alloys. In addition, dexamethasone (DEX), a syn-
thetic glucocorticoid,33 with its high potency and effectiveness against inflammation34 has 
been chosen as anti-inflammatory drug model. We hypothesize that DEX release of at 
bone-implant interface, will attenuate the inflammatory response induced by wear debris 
without causing the adverse side effects reported for oral administration e.g. gastrointes-
tinal bleeding and perforation.35 We further hypothesize that, by preparing TiO2 particles 
loaded with DEX through different synthetic routes, different level of drug loading, differ-
ent release kinetics and subsequentcy different anti-inflammatory efficiency will be ob-
tained. Considering these hypothesis, TiO2 particles were prepared by modifying the sur-
face of TiO2 through amino and mercapto synthetic routes for subsequent attachment of 
DEX. 
One of hallmarks of inflammation is the recruitment and activation of macrophages,36,37 
that produce a variety of inflammatory mediators e.g. interleukins, prostaglandins and 
reactive species such as highly reactive free radicals and nitric oxide (NO).38,39 To assess 
the anti-inflammatory properties of the model-system developed, we evaluated the effect 
of dexamethasone released from TiO2 particles on cytoxicity and LPS-induced NO and 
  
 
 
TNF-a production in a macrophage-like cell line (Raw 264.7) and compared its perfor-
mance to dexamethasone phosphate (DEX-P) that is currently used in clinical practice.  
2 Experimental 
2.1 Chemicals 
Titanium (IV) oxide (Anatase, <25nm), (3-mercaptopropyl) trimethoxysilane (MPTMS, 
95%), (3-Aminopropyl)triethoxysilane (APTS, 99%), succinic anhydride (≥99%), Dexa-
methasone (Dex, >97%), 4-pentenoic acid (≥98%, FG), 1-(3-Dimethylaminopropyl)-3-
ethyl-carbodiimide hydrochloride (EDC, 98+%), N-hydroxysulfosuccinimide (Sulfo-NHS, 
98%), N-morpholino ethanesulfonic acid (MES) hydrate (>99.5%), Phosphate buffer so-
lution (PBS) tablets, Sodium acetate trihydrate (≥99%), sodium chloride (ACS reagent, 
≥99%), citric acid monohydrate (ACS reagent, ≥99%), disodium phosphate (ACS rea-
gent, ≥99%) were purchased from Sigma-Aldrich, UK. HPLC grade acetonitrile, Glacial 
Acetic Acid, Methanol, Dichloromethane (DCM) and Toluene were purchased from 
Fisher, UK. All other chemicals were analytical reagent grade, stored according to man-
ufacturer's guidelines and used as received. 
2.2 Dexamethasone-functionalized TiO2 particles synthesis 
The synthesis of Dex-TiO2 particles was achieved using a two-steps surface functionali-
zation process; first the TiO2 particles were surface modified using silane agents, fol-
lowed by carboxyl functionalization (Figure 1). The second step was the dexamethasone 
attachment, based on the covalent bond formation between the carboxylic acid groups 
on functionalized TiO2 particles (TiO2-COOH) and the dexamethasone-hydroxyl groups. 
Surface modification with silane agents and carboxyl functionalization steps are different 
for each route, whereas the step of dexamethasone conjugation was the same for amino- 
and mercapto-functionalized TiO2 particles.  
  
 
 
2.2.1 Surface functionalisation  
In a typical synthesis, 1 g of TiO2 particles were dispersed in 15 mL of anhydrous toluene. 
The TiO2 particles surface was functionalized with amine or mercapto groups by adding 
100µl of either APTS (amino route) or MPTMS (mercapto route), respectivelly, under 
stirring and incubating for 24 hours. Subsequently, the functionalized particles (TiO2-NH2 
or Ti-SH) were isolated by centrifugation at 14000 rpm for 5 minutes (LE-80K Ultracen-
trifuge, Beckman Coulter, UK) at 20°C followed by washing for at least three cycles. The 
resulting particles were dried under the fume hood for 24 hours.  
Amine-functionalized particles (TiO2-NH2) (250 mg) were dispersed in 100 mL of DCM 
and purged with nitrogen. Succinic anhydride (25 mg) was dissolved in 2.5 mL of DCM 
and added to the reaction mixture to obtain carboxylic acid functionalized surface. This 
suspension was kept under nitrogen for 18 hours under constant stiring. Subsequently, 
the succinilated particles suspension was separated by centrifugation at 14000 rpm for 
5 minutes at 20°C (LE-80K Ultracentrifuge, Beckman Coulter, UK) followed by washing 
for at least three cycles with methanol to remove unreacted materials. The resulting par-
ticles were dried under the fume hood for 24 hours.   
Thiol-functionalized (Ti-SH) particles (250 mg) were dispersed in 100 mL of methanol: 
water (2:1) solution and 4-pentenoic acid (25mg) was added. This suspension was kept 
under ultraviolet using a UV lamp (UVGL-58, Cambridge, UK) λ = 254 nm for approxi-
mately 3 hours. The particles were separated by centrifugation at 14000 rpm for 5 
minutes at 20°C (LE-80K Ultracentrifuge, Beckman Coulter, UK) followed by washing for 
at least three cycles with methanol to remove unreacted materials. The resulting particles 
were dried under the fume hood for 24 hours.   
2.2.2 Dexamethasone loading 
50 mg of dexamethasone were dissolved in 100 mL MES buffer (0.1 M, pH 6.0). This 
solution was used to disperse 250mg of carboxyl functionalized particles (Amino or 
  
 
 
Mercapto route), 10 mg EDC and 10 mg Sulfo-NHS. The suspension was kept under 
vigorous mixing for 24 hours, at room temperature. Dexamethasone-loaded particles 
were recovered by centrifuging at 14000 rpm for 5 minutes at 20°C by washing for at 
least three cycles. Then dexamethasone loaded particles were left to dry under the fume 
hood for 24 hours.  
2.3 Particles characterization 
2.3.1 Transmission electron microscopy (TEM) 
Images of particles were obtained using a Zeiss 902 transmission electron microscope 
(TEM) operating at a voltage of 80 kV. The aqueous dispersion of the particles was drop-
cast onto a carbon-coated copper grids, and grid was dried at room temperature (20ºC) 
before loading into the microscope (direct deposition). The average particle size, size-
distribution and morphology analysis of the samples was carried out from transmission 
electron micrographs using ImageJ for Windows (Version 1.50i). 
2.3.2 Zeta potential measurements 
The electrophoretic mobility was determined by dynamic light scattering (DLS) with a 
Malvern Zetasizer, Nano ZS particle characterization system (Malvern Instruments Lim-
ited, UK). Zeta potential values were calculated by the Smoluchowski's relation/approxi-
mation, converting electrophoretic mobility to zeta potential values. The measurements 
were performed in a folded capillary cell. For measuring zeta potential, 1mg of particles 
was dispersed in 1mL of buffer solution using the vortex and the ultrasonic bath (~30min), 
then the suspension was immediately transferred into the capillary cell. For pH 4, 5, and 
6 an acetic acid/sodium acetate buffer (0.01 M) was employed. As for pH 7, Sodium 
Chloride (NaCl) buffer (0.01 M) was utilized. Results are given as the average± standard 
deviation of three measurements on three independent replicates. 
  
 
 
2.3.3 Thermogravimetric analysis (TGA) 
Thermogravimetric analysis (TGA) was performed using a Perkin-Elmer TGA 4000 in-
strument. The samples were heated from 50 to 800 °C with a constant heating rate of 10 
°C/min. Weight loss percentage of each sample was calculated relative to the initial sam-
ple weigth, prior to heating. As for organic material content was calculated as weight loss 
(%) when the line plateaus (approximately around 800°C); while inorganic matter was 
assumed to be the remaining particles component. 
2.3.4 Fourier Transformed Infra-Red (FTIR) 
FT-IR spectra were recorded on a Shimadzu IRAffinity-1S apparatus equipped with ATR 
diamond accessory, at room temperature between 4000 and 500 cm-1 with 4 cm-1 reso-
lution running 16 scans. 
2.4 Dexamethasone release profile   
Dexamethasone loaded-particles were dispersed (10 mg/ml) in citric acid-disodium 
phosphate buffer (0.1 M) at pH ranging from 4 to 7. Samples were incubated statically at 
37°C and every 24h the particles were separared from the suspension, thus the super-
natant was collected to analyse dexamethasone release, and redispersed in fresh buffer. 
The amount of dexamethasone released was quantified using reverse-phase High Per-
formance Liquid Chromatography (rp-HPLC) system with 1100 series Agilent Technolo-
gies HPLC. The mobile phase was a mixture of PBS:acetonitrile:glacial acetic acid 
70:26:4 at a fixed flow rate of 1 mL/min. Samples of 10 µL were injected and detected 
by UV at 244 nm. The analytical column was Water Spherisorb ODS2 column (Pore size- 
80Å, 5 µm, and width x length- 4.6 mm X 150 mm). To evaluate the concentration of 
dexamethasone in the samples collected, a calibration curve of the HPLC detection of 
dexamethasone was previously obtained. All experiments were performed in triplicate. 
  
 
 
2.5 Cell culture and treatments 
RAW 264.7 cells were obtained from European Collection of Cell Cultures (ECACC). 
cells were grown in DMEM medium containing 10% fetal bovine serum and 100 U/mL of 
penicillin/streptomycin, under 5% CO2 at 37°C, in humidified air. Cell numbers and via-
bility were assessed by the trypan blue dye-exclusion method. Cells were seeded at a 
density of 2x104 cells/well in a 96 well-plate and permitted to adhere over a 4-5 hours 
period. Cells were then treated with DEX-P (3.9 µg/ml) or elutes/broths of functionalized 
TiO2 particles collected from drug release studies (sterilized through filtering)  containing 
the same amount of DEX. The concentration of DEX-P was determined in preliminary 
experiments as that capable of reducing inflammation without affecting viability (supple-
mentary material). DEX-P solutions were prepared at 39 µg/ml and release buffers were 
diluted to the same concentration, these solutions were then added to the cell medium 
in a ratio 1:10 to reach the final concentration of 3.9 µg/ml. Because the maximum con-
centration of DEX achieved from the mercapto route was not enough to allow this dilution 
and cells did not grow/survive higher concentrations of buffers, these particles were not 
investigated further. 
After incubation for 1 hour, LPS (1 µg/ml) was added to stimulate the macrophages and 
they were cultured for up to 3 days. Biological responses (cell viability, NO and TNF-a 
production) were assessed at different time points (18, 24, 48 and 72 hours). The effect 
of DEX in the absence of LPS was also assessed, to observe whether it induced changes 
in basal levels of assays performed.  
2.6 Biological assays 
2.6.1 Methylthiazolyl Tetrazolium (MTT) assay 
Cellular viability/proliferation of cells after being exposed to dexamethasone was as-
sessed using the mitochondria dependent reduction of Methylthiazolyl Tetrazolium 
(MTT) to formazan. After incubation with dexamethasone the culture medium was 
  
 
 
removed and 20 μL of the MTT solution (5 mg/mL) was added to each well, and incu-
bated at 37°C in a humidified 5% CO2 atmosphere, for another 4 hours. The supernatant 
was then carefully discarded and 100µL of Dimethyl sulfoxide (DMSO) were added to 
each well to solubilize formazan. The absorbance at 540 nm was measured using ELISA 
reader. Results are expressed as a percentage of the respective control (with or without 
LPS). 
2.6.2 Measurement of nitrite oxide (NO) levels 
100 μl of cells culture supernatant was mixed with the same volume of Griess reagent 
(Thermo Fisher Scientific) for 30 min at room temperature. Then the nitrite produced was 
determined by measuring optical density of the mixture at 548 nm in a microplate reader. 
Nitrite was quantified by an external standard, using potassium nitrate (KNO3). Results 
are expressed as a percentage of the respective control (with or without LPS). 
2.6.3 Measurement of TNF-a levels 
Tumor necrosis factor alpha (TNF-a) released by macrophages cells were determined 
using the appropriate ELISA kit (Sigma, UK) following the manufacturer recommended 
protocol. 
2.7 Statistical analysis 
Unless stated otherwise, all the tests described above were performed with at least  3 
independent experiments (each experiment had 3 replicates) and all data were subject 
to a one-way analysis of variance (ANOVA) to assess the statistical significance of re-
sults between groups. Experimental results were considered statistical significant at 
95 % confidence level (p<0.05). Tukey’s multiple comparisons post hoc test was per-
formed between all groups.  All analyses were run using the SPSS software. 
  
 
 
3 Results and Discussion 
In this study a dexamethasone delivery system was developed through the surface func-
tionalization of TiO2 particles using different approaches, amino ad mercapto. The utili-
zation of different routes was applied to assess if different linkers i.e. functional groups 
between dexamethasone and TiO2 particles could affect the loading efficiency of dexa-
methasone, drug release profile and also cellular behaviour e.g. toxicity, bioactivity. Sur-
face functionalization and dexamethasone loading efficiency, zeta potential measure-
ments and TGA analysis were performed to provide evidence of different organic group 
attached i.e. -NH2, -SH on the surface of TiO2 particles, including dexamethasone load-
ing.  
3.1 Characterisation of Dex-loaded TiO2 particles 
3.1.1 Determination of morphology and average size  
Examples of TEM images of the uncoated TiO2 particles and functionalized ones (Figure 
2), were taken to determine the shape/structure and size of the particles after each step 
of functionalization. Unfunctionalised TiO2 particles radius was around 20-25 nm with a 
narrow size distribution. Moreover, they showed a cubical and spherical-like shape with 
dense core which is characteristic of TiO2 nanoparticles. After each step of functionaliza-
tion (amino, carboxyl and DEX loading) the size of particles diameter remained around 
25-30 nm, without obvious morphological changes. A similar trend was observed for 
mercapto route functionalization particles (shown in the supplementary material). 
Overall, images obtained via transmission electron microscopy, revealed that for all syn-
thetic routes tested the different steps of TiO2 particles functionalization, did not damage 
the particles structure. It also revealed that the thickness of the functionalizing layer was 
negligible.  
  
 
 
3.1.2 Zeta potential measurements  
Zeta potential measurements were used to assess the attachment of organic groups i.e. 
-NH2, -SH, -COOH, after each step of TiO2 particles functionalization, including dexame-
thasone loading (Figure 3). As pH becomes more alkaline, a decrease on surface poten-
tial was observed; on the other hand, the highest surface potentials were observed under 
acidic pH. A more positive surface charge was observed after amino and mercapto-func-
tionalization when compared with bare TiO2 particles. On the other hand, carboxyl func-
tionalized and dexamethasone loaded-TiO2 particles, showed a more negative surface 
charge than amino and mercapto- functionalized particles. 
These results can be explained based by the ability of protons to neutralize negativelly 
charged groups at low pH values. The positive surface charge observed after amino-
functionalization of TiO2 particles can be related to the amino groups (-NH2) ability of 
accepting protons, becoming positively charged (NH3+). On the other hand, the decrease 
of zeta potential under alkaline conditions (pH>6), can be attributed to the deprotonation 
of the amino group on the surface of TiO2 particles. In contrast, lowest surface potentials 
were observed for succinic anhydride and pentanoic-acid TiO2 particles, especially for 
more alkaline pH values. A possible explanation for this character could be attributed to 
presence of carboxylic acid (–COOH) groups on surface of the particles, which exhibit a 
more negative character than NH2- and SH-TiO2 particles. The same behavior i.e. more 
negative surface potential was observed after dexamethasone loading, for both mer-
capto and amino route. The higher negative zeta potential observed might be attributed 
to the presence of functional groups (-OH and -C=O) of dexamethasone which are on 
the surface of the TiO2 particles. In particular the fluorine group (9-Fluoro) that has been 
described to affect the electron density of its “neighbors” i.e. functional groups.50 In this 
specific case, fluorine seems to be responsible for decreasing the pKa value of hydroxyl 
moiety (11, 17, 21-trihydroxy) on dexamethasone, thus resulting in a more negative zeta 
  
 
 
potential after dexamethasone loading. Similar results were described by Fratoddi et al., 
that obtained a negative zeta potential after loading particles with dexamethasone under 
alkaline conditions i.e. aqueous particles suspension.51  
3.1.3 Thermogravimetric analysis (TGA) 
The TGA profile of TiO2 particles after each functionalization step revealed an initial 
weight loss (~1%) at about 100°C (Figure 4), which is normally attributed to the evapo-
ration of adsorbed water from the samples. Due to this reason, the organic content of 
each sample (Table 1) was calculated based on the weight loss beyond 100°C, that truly 
corresponds to the combustion of organic species. It was also observed that, after each 
functionalization step, there was an increased amount of organic content on the surface 
of TiO2 particles. 
Results from TGA analysis (Table 1 and Figure 4) showed an increase of organic content 
after amino and carboxyl functionalization when compared with organic content of TiO2 
particles (1.5%); 6.0% for amino-TiO2 particles and 9.2% for carboxyl-functionalized TiO2 
particles. Moreover, the same behaviour was observed for DEX loaded particles, where 
an increase of organic content of approximately 6% was detected when compared to 
carboxyl-functionalized TiO2 particles.  
An increase of organic content was observed after mercapto and carboxyl functionaliza-
tion when compared with organic content of TiO2 particles (1.5%), 4.8% for mercapto-
TiO2 particles and 5.4% for carboxyl-functionalized TiO2 particles. Moreover, the same 
behavior was observed for DEX loaded particles, where an increase of organic content 
to approximately 9.2% was detected when compared to carboxyl-functionalized TiO2 par-
ticles (5.4% of organic content). 
TGA profile obtained was similar and in agreement to the one obtained by Bach  et al. 
2012.40 The TGA profile of particles obtained via amino  and mercapto route (Figure 4) 
showed an increase of organic material of approximately 3.1% after APTES and of 2.6% 
  
 
 
after MPTS-functionalization, thus confirming the successful attachment of amino and 
mercapto functional groups on the surface of TiO2 particles.  
The lower load achived through the mercapto route could be attributed to the lower effi-
ciency in the reaction between the SH grous and the pentanoic acid as seen in both the 
TGA and the FTIR analysis, as this route gave fewer COOH groups on the surface, it 
can be expected that the conjugation of DEX would result in fewer molecules of the drug 
attached. 
  
 
 
3.1.4 Fourier Transformed Infrared (FTIR) spectral studies  
The spectra of functionalized and untreated-TiO2 are shown particles in 
 
  
 
 
Figure 5. FTIR spectrum of untreated-TiO2 nanoparticles showed a broad peak appear-
ing at 3100–3600 cm–1 due to vibrations of hydroxyl groups.40 The absorption peak 
around 1620 cm−1 was caused by bending vibration of coordinated H2O as well as from 
the hydroxyl groups on TiO2 surface.41 Moreover. the intense broadband in the vicinity of 
800 cm−1 was attributed to the stretching vibration of Ti–O–Ti in anatase morphology.42 
When comparing with the spectra for untreated-TiO2 particles, a new peak located at 
around 1360 cm-1 in the spectra of NH2-TiO2 particles appeared, which can be assigned 
to carbon-nitrogen bonds. The presence of the previous described bands and peaks on 
the FTIR spectrum of amino-functionalized and untreated TiO2-particles are in reasona-
ble agreement with those reported in the literature.43 The COOH-TiO2 particles spectra 
showed a new peaks around 1690 cm-1 indicating the presence of –C=O stretching vi-
bration band.44 These findings suggested that carboxyl groups were present onto the 
surface of the particles after successful succinalition. 
When comparing bare-TiO2 particles with those functionalised with mercapto-silane 
(MPTES), the band corresponding to thiol (SH) groups could be clearly observed at 
around 2400 cm-1 (inset Figure 5b). Moreover, the bands at ~3000 cm-1 and 2800 cm-1 
attributed to the C–H stretch of methylenes of the alkyl chain were obvious, suggesting 
the new functional groups were successfully attached to the surface of TiO2 particles.45 
The other visible peaks between 900 and 1100 cm−1 are due to Si–O–Si and Si–O 
stretching vibrations; additionally, the O–H broad peak (3100–3600 cm-1) which ap-
peared in the spectrum of bare-TiO2 particles, was less visible, which coincides with a 
decrease in the hydroxyl groups due to the attachment of the MPTES.46  
As for carboxyl and DEX functionalisation, the FTIR equipment was not sensitive enough 
to detect the characteristic peaks/bands. Although different FTIR spectra were observed, 
particularly a broad peak between 3100–3600 cm-1 was visible, which coincides with the 
  
 
 
increased presence the hydroxyl groups (O–H) due to the attachment of COOH func-
tional and OH groups on surface of functionalised-TiO2 particles. 
3.2 Dexamethasone release profile 
in vitro release studies were performed under different joint conditions, healthy joints 
(pH=~7) 47 and inflamed joints, which are associated with local acidosis.48 For most of 
the conditions tested (pH=5, 6 and 7), dexamethasone was released within the first 24 
hours (Figure 6). Although, at pH=4, dexamethasone release from TiO2 particles ob-
tained via amino route was prolonged, where the drug was constantly released for 6 
days. Moreover, for both amino and mercapto particles, the drug release was pH-de-
pendent; for particles obtained via amino route concentration of dexamethasone in-
creases with decreasing pH. Oppositely for particles obtained via mercapto route the 
highest release of dexamethasone was obtained under physiological conditions (pH=7).  
Because the maxium concentration of DEX achieved from the mercapto route was not 
sufficient, these particles were not investigated further (for the biological assays). 
Dexamethasone release profile was expected to mainly depend on the structure and 
hydrolysis rate of the linker between dexamethasone and TiO2 particles 52 both of which 
are strongly affected by the type of synthetic route i.e. amino, mercapto utilized in this 
study.  
Results show that for particles obtained via amino route (Figure 6a), DEX release kinetics 
was faster under the most acidic conditions (pH=4); moreover, in this conditions release 
continued over a period of 6 days, a behavior which was only observed for this pH value. 
Dexamethasone was conjugated to the TiO2 particles through ester bonds, hence its 
relaese was due to hydrolysis of this bond. The rate of this reaction increases the further 
from neutrality, thus leading to the gradually greater release of dexamethasone from 
pH=7 to pH=4. A similar drug release profile was observed by Nuttelman et al.52 where 
  
 
 
dexamethasone was covalently attached to Polyethylene glycol) (PEG)-based hydrogel 
scaffold and for gentamicin when attached to gold 53 and silica.49 
As for mercapto route (Figure 6b) results showed that dexamethasone presented a less 
efficient, and with lower drug concentrations, release when compared to amino route. 
Furthermore, when comparing the overall drug released from amino and mercapto par-
ticles, it can be easily seen that a higher amount of dexamethasone was released when 
amino route was employed. This drug release profile is in agreement with TGA analysis 
which reveals that a higher % of organic content was observed after dexamethasone 
attachment to amino-TiO2 particles when compared to the ones obtained via mercapto 
route (Table 1). However, despite DEX loading achieved through the mercapto route was 
only marginally lower than the amino route, the release was considerably lower (Figure 
6). This is likely due to the more difficult hydrolysation of the ester bond between DEX 
and functionalized surface when the mercapto route was employed. The ester bond is 
the same in both amino and mercapto route, although the number of carbon differs: 4 for 
amino route and 3 for mercapto route (Figure 1). This variation on the number of carbon 
groups, could also explain the more efficient release of dexamethasone when amino 
route was applied, where the longer the linker the easier the hydrolysis of the ester bond 
as more the assess required by nucleophiles compounds to initiate hydrolysis is less 
sterically hindered. 
The time-frame aspects of anti-inflammatory drug release that will modulate the foreign 
body response to implant are still not well understood. Although It is known that to obtain 
an efficiently modulation of inflammatory response, the release of drug should at least 
be continuous.56 Taking into account that the inflammatory tissue response starts after 
the first seconds after device implantation, 55 the immediate dexamethasone release i.e. 
within first 24 hours observed from both mercapto and amino TiO2 particles could be 
  
 
 
highly favorable to control initial acute inflammation (1-3 days) at the site of implantable 
devices.56  
3.3 Cellular viability studies 
Results obtained from MTT assay showed that the viability of cells exposed to DEX re-
leased from functionalised-particles obtained through amino route for different periods of 
time was very similar (>90% cellular viability) to the one observed for the same concen-
tration of pure DEX administed as DEX-P (Figure 7).  
3.4 Anti-inflammatory activity of Dexamethasone-loaded TiO2 particles 
The anti-inflammatory activity of DEX released from the model system (DEX-loaded 
functionalised TiO2 particles) obtained by amino synthetic route was compared to the 
anti-inflammatory activity of same concentration of pure DEX administed as DEX-P.  
Exposure to DEX-P reduced the amount of NO produced by RAW 264.7 cells stimulated 
by LPS; similarly DEX released from the functionalized surfaces decreased NO produc-
tion (Figure 8). TNF-a data showed a similar inhibitory trend to that observed for NO 
production (Figure 9). 
In general, implants, such as TJR, induce tissue response after implantation into living 
tissues.58 During the inflammatory process, NO and cytokines such as TNF-α are re-
leased, and thus they can be utilized for measuring the inflammatory reactions level after 
material implantation, including aseptic periprosthetic osteolysis.57 There is a considera-
ble body of evidence showing that there is an increased presence of TNF-α and NO in 
the fluid and inflamed periprosthetic membrane tissue obtained from loosened im-
plants.61-63 Because of its pivotal role in anti-inflammatory activity of macrophages, sig-
nificant effort has been dedicated to developing therapeutic agents that regulate/de-
crease NO and TNF-α production.  
A preliminary study (as shown in the supplementary material) was performed to deter-
mine the optimal DEX concentration capable of reducing the antiinflammatory activity, 
  
 
 
and simultaneously not impact cell viability, of Raw 264.7 macrophages. For this pur-
pose, Raw 264.7 macrophages with and without LPS were exposed to a range of DEX 
concentrations (3.9-100µg/mL).  
As it was observed for DEX alone, DEX released from functionalised-TiO2 particles ob-
tained by amino route decreased both NO and TNF-α production in LPS-activated mac-
rophages (Figure 8 and Figure 9). Together with results obtained from cellular viability 
studies (viability>80%) (Figure 7), the anti-inflammatory efficacy of model system re-
ported here was confirmed excluding the hypothesis of a non-specific decline in protein 
synthesis due to drug-induced toxicity. Similar effect was observed in previous studies 
where the anti-inflammatory compounds tested have shown to simultaneous reduce 
LPS-induced nitrite accumulation and TNF-α secretion in RAW 264.7 macrophages.64 
Similar studies have reported the anti-inflammatory effect of DEX released from drug-
eluting systems.51,67  
Furthermore, it is important to highlight the biological relevance of this study, which sim-
ultaneous focuses on inhibition of different inflammatory mediators NO and TNF-α; and, 
also in contrast to most part of the studies reported in literature, the anti-inflammatory 
effect was assessed for longer period (i.e. 72h study instead of 18h/24h). Hence, from a 
biological point of view, the results obtained in this study provide a more comprehensive 
and consistent information about the anti-inflammatory mechanism of the model system 
developed here; particularly anti-inflammatory efficacy lasting  3 days as reported in this 
study, suggests that our model system will modulate the acute inflammatory phase (~2-
3 days) thus avoiding the unfavourable chronic phase. In addition, DEX released from 
functionalised-particle was added to the cells, just before LPS addition. This observation 
might be of special importance to elucidate the mechanisms of action of an anti-inflam-
matory eluting implant, particularly as a protective compound to avoid chronic inflamma-
tion. Moreover, despite being released from a cross-linking agent, DEX retained almost 
  
 
 
the same antiinflamatory activity; in the amino route there are two possible bonds that 
could be hydrolised, one is amide bond between the nitrogen of APTS and the succininc 
anhydrade and the other is the ester bond between DEX and the succininc acid. Ester 
bonds are more easily hydrolised than amide ones thus it was hypotised that the release 
would generate pure DEX molecules; the antiinflammatory results prove this along with 
demonostarting the efficacy of our technology.  
4 Conclusion  
Despite being one the most common complication of TJR, there is no approved therapy 
to avoid or treat aseptic loosening following wear-induced periprosthetic inflamma-
tion/osteolysis. Considerable research has been done to reduce wear debris release and 
their consequences, including modification on implants design and improvement of sur-
gical techniques, although offering some promise none of these approaches have yet 
shown to inhibit or reverse particle-induced osteolysis in a human population. This leads 
to the conclusion that most part of the currently applied therapies, depend on the sys-
temic administration of anti-inflammatory agents, meaning that their bioavailability at os-
teolytic lesions will mainly depend on the limited blood supply at bone-interface implant. 
Therefore, localised release of anti-inflammatory drugs from implanted TJR could mod-
ulate the environment of this host cell/implant interface and related inflammatory events. 
Thus, overcoming the aseptic loosening and improve performance of these life-saving 
devices. 
In this study different routes were applied to develop a drug delivery model system, that 
allows localized and tuneable delivery of anti-inflammatory drugs.  
Overall, results have also shown that, depending on the synthetic route applied, the DEX-
loaded-functionalised TiO2 particles obtained present different features from size/mor-
phology to drug release profiles.  
  
 
 
Furthermore, in vitro studies using Raw 264.7 macrophages indicated that DEX concen-
trations released from functionalised-TiO2 particles presented anti-inflammatory activity; 
particularly DEX released from surfaces functionalized through the amino route exhibited 
antiinflamatory activity comparable to the same concentration of pure DEX. 
Therefore, this model system could be a potential approach for patients which undergo 
TJR, to avoid progressive osteolysis and/or to patients who need repeated revision sur-
gery after joint replacement. 
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Table 1. Organic contant of samples after each step of synthesis as determined through 
TGA. 
Synthetic route Samples Organic content (%) 
 TiO2 Particles 1.6±0.1 
 Mercapto-TiO2 Particles 4.8±0.2 
MERCAPTO **Carboxyl-TiO2 Particles 5.4±0.3 
 Dex-TiO2 Particles conjugated 9.2±0.4 
 Amino-TiO2 Particles 6.0±0.3 
AMINO *Carboxyl-TiO2 Particles 9.2±2.6 
 Dex-TiO2 Particles conjugated 14.8±0.2 
Carboxyl functionalization was performed via *succinic anhydride and **Pentanoic-acid. 
 
 
  
  
 
 
List of Figure captions 
Figure 1. Detailed shemes of chemical reactions for dexamethasone-TiO2 particles (1) 
silane functionalization, followed by (2) carboxyl functionalization, and then (3) dexame-
thasone attachment, for amino and mercapto routes. Functional groups on TiO2 particles 
surface are highlighted with blue color. 
 
Figure 2. Examples of transmission electron microscopy (TEM) images different surface-
modified TiO2 particles: (a) TiO2 particles, (b) amino-functionalized, (c) succinilated 
amino functionalized, (d) Dex-loaded TiO2 particles.  Bar represents 100 nm. 
 
Figure 3. Zeta potentials of different surface-modified TiO2 nanoparticle suspensions at 
different pH values for amino (a) route: TiO2 bare NP (-); amino functionalized TiO2-NH2 
(-); succinilated amino functionalized TiO2-COOH (-);DEX conjugated to succinilated 
amino functionalized TiO2-COOH (-) and for and mercapto (b) route: TiO2 bare NP(-); 
mercapto functionalized TiO2-SH (-); carboxyl mercapto functionalized TiO2-COOH (-); 
DEX conjugated to succinilated mercapto functionalized TiO2-COOH (-). 
 
Figure 4. Thermograms of different surface-modified TiO2 particles prepared through 
amono (a) and mercapto route (b). 
  
 
 
 
Figure 5Figure 5/ FTIR spectra of TiO2 bare NP (-); amino functionalized TiO2-NH2 (-); 
succinilated amino functionalized TiO2-COOH (-); DEX conjugated to succinilated amino 
  
 
 
functionalized TiO2-COOH (-); mercapto functionalized TiO2-SH (-); carboxyl mercapto 
functionalized TiO2-COOH (-); DEX conjugated to succinilated mercapto functionalized 
TiO2-COOH (-). 
 
Figure 6. Cumulative release of dexamethasone from TiO2 particles obtained via amino 
route (a) and mercapto route (b) under different pH conditions. 
 
Figure 7. Effect of DEX on cell viability of LPS-activated RAW 264.7. Cells were exposed 
to DEX (3.9 µg/mL) either from filtered broth collected after the first 24h of release (black 
columns) or DEX-P for 18, 24, 48 and 72 hours (light gray columns). Cellular viability 
was assessed by MTT assay. 10% PBS buffer was used as positive control (dark grey 
columns). 
 
Figure 8. Effect of DEX on on nitric oxide (NO) production (% to NO in LPS only control) 
of LPS-activated RAW 264.7. Cells were exposed to DEX (3.9 µg/mL) from filtered broth 
collected after the first 24h of release (black columns)  or DEX-P (DEX equivalent 3.9 
µg/mL) (gray columns)  for 18, 24, 48 and 72 hours. Culture supernatants were collected 
and analysed by Griess reagent.  
 
Figure 9. Effect of DEX on TNF-a production (% to TNF-a in LPS only control) of LPS-
activated RAW 264.7 macrophages. Cells were exposed to DEX (3.9 µg/mL) from filtered 
broth collected after the first 24h (black columns) of release or DEX-P (DEX equivalent 
3.9 µg/mL) (gray columns) for 18, 24, 48 and 72 hours. 
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